請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59012完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 余家利 | |
| dc.contributor.author | Hui-Ying Chen | en |
| dc.contributor.author | 陳惠瑩 | zh_TW |
| dc.date.accessioned | 2021-06-16T08:44:27Z | - |
| dc.date.available | 2013-09-24 | |
| dc.date.copyright | 2013-09-24 | |
| dc.date.issued | 2013 | |
| dc.date.submitted | 2013-08-21 | |
| dc.identifier.citation | 中文資料
1. 行政院內政部(2009) 性別統計指標, 婚姻與家庭http://sowf.moi.gov.tw/stat/gender/list03.html 2. 行政院衛生署國民健康局,97年出生通報年報統計表 http://www.bhp.doh.gov.tw/BHPnet/Portal/Them_Show.aspx?Subject=200712250049&Class=2&No=200908180001 3. 謝君柔,少子化浪潮下大臺北地區不願生育女性觀念之研究(碩士論文,國立臺灣大學,2006) 4. 郭義興,台灣母血唐氏症篩檢對唐氏症出生趨勢之影響(碩士論文,國立臺灣大學,2003) 5. 任怡慧,以唐氏症血清篩檢法作為偵測孕婦中胎兒染色體異常之探討(碩士論文,國立臺灣海洋大學,2006) 6. 陳淑蘭,高危險妊娠孕婦在第三孕期之不確定感, 壓力及因應策略(碩士論文,高雄醫學院,1996) 7. 林家君,第一孕期胎兒頸部透明帶厚度測量與第二孕期生化試驗於偵測胎兒染色體異常(碩士論文,國立中興大學,2004) 8. 張瓊懿譯(2013)。生命的關鍵決定。台北:行人。Peter A.Ubel (2012).Critical Decisions.-How you and your doctor can make the right medical choices together. 英文資料 1. Chasen ST, Skupski DW, McCullough LB, Chervenak FA. Prenatal informed consent for sonogram: the time for first-trimester nuchal translucency has come. J Ultrasound Med. 2001; 20: 1147-52. 2. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol. 2007 Jan;109(1):217-27 3. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. One stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: A prospective study of 15,030 pregnancies. Ultrasound Obstet Gynecol 2002; 20: 219-25. 4. Chen M, Lee CP, Lam YH, Tang RY, Chan BC, Wong SF, Tse LH, Tang MH. Comparison of nuchal and detailed morphology ultrasound examinations in early pregnancy for fetal structural abnormality screening: a randomized controlled trial. Ultrasound Obstet Gynecol 2008;31:136-146 5. Cuckle HS, Wald NJ, Thompson SG. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol. 1987 May; 94(5):387-402. 6. Crossley JA, Aitken DA, Cameron AD, McBride E, Connor JM. Combined ultrasound and biochemical screening for Down’s syndrome in the first trimester: a Scottish multicentre study. BJOG 2002; 109: 667-76. 7. Down LJ. Observations on an ethnic classification of idiots. Clin Lectures and Reports, London Hospital 1866;3:259–62 8. Morris JK,Wald NJ,Watt HC.Fetal loss in Down syndrome pregnancies. Prenat Diagn 1999; 19: 142–145. 9. Mulvey S, Wallace EM. Women's knowledge of and attitudes to first and second trimester screening for Down's syndrome. BJOG 2000; 107: 1302-5. 10. Benn P, Wright D, Cuckle H. Practical strategies in contingent sequential screening for Down syndrome. Prenat Diagn 2005; 25: 645–652. 11. Vadiveloo T, Crossley JA, Aitken DA. First-trimester contingent screening for Down syndrome can reduce the number of nuchal translucency measurements required. Prenat Diagn 2009; 29: 79–82. 12. Vandecruys H, Faiola S, Auer M, Sebire N, Nicolaides KH. Screening for trisomy 21 in monochorionic twins by measurement of fetal nuchal translucency thickness. Ultrasound Obstet Gynecol 2005; 25: 551–553. 13. Spencer K, Liao A, Skentou H, Cicero S, Nicolaides KH. Screening for Triploidy by fetal nuchal translucency and maternal serum free β-hCG and PAPP-A at 10–14 weeks of gestation. Prenat Diagn 2000; 20: 495–499. 14. Schuchter K, Hafner E, Stangl G, et al. The first trimester ‘combined test’ for the detection of Down syndrome pregnancies in 4939 unselected pregnancies. Prenat Diagn 2002; 22: 211–215. 15. Sahota DS, Leung TY, Chan LW, et al. Comparison of first-trimester contingent screening strategies for Down syndrome. Ultrasound Obstet Gynecol 2010; 35: 286–291 16. Cuckle HS, Malone FD, Wright D, et al. Contingent screening for Down syndrome—results from the FaSTER trial. Prenat Diagn 2008; 28: 89–94. 17. Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free β-hCG and pregnancy-associated plasma protein-A. 2008; Hum Reprod 23: 1968–1975. 18. Papageorghiou AT, Avgidou K, Spencer K, Nix B, Nicolaides KH. Sonographic screening for trisomy 13 at 11 to 13(6) weeks of gestation. Am J Obstet Gynecol 2006; 194: 397–401 19. Nyberg DA, Souter VL, El-Bastawissi A, et al. Isolated sonographic markers for detection of fetal Down syndrome in the second trimester of pregnancy. J Ultrasound Med 2001; 20: 1053–1063. 20. Nicolaides KH.. Screening for chromosomal defects. Ultrasound Obstet Gynecol 2003; 21: 313–321. 21. Maiz N, Valencia C, Kagan KO, Wright D, Nicolaides KH. Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11–13 weeks of gestation. Ultrasound Obstet Gynecol 2009; 33: 512–517. 22. Malone FD, Canick JA, Ball RH, et al. First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or secondtrimester screening, or both, for Down’s syndrome. N Engl J Med 2005; 353: 2001–2011. 23. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. Fetal Medicine Foundation First Trimester Screening Group.UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchaltranslucency thickness at 10–14 weeks of gestation. Lancet 1998; 352: 343–346. 24. Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 2004; 191: 45–67. 25. Agathokleous et al. Meta-analysis of second trimester markers for trisomy 21 Ultrasound Obstet Gynecol. 2013 Mar;41(3):247-61 26. Tsaliki E, Papageorgiou EA, Spyrou C, Koumbaris G, Kypri E, Kyriakou S, Sotiriou C, Touvana E, Keravnou A, Karagrigoriou A, Lamnissou K, Velissariou V, Patsalis PC.MeDIP real-time qPCR of maternal peripheral blood reliably identifies trisomy 21. Prenat Diagn. 2012 Oct;32(10):996-1001 27. Lo YM. Non-invasive prenatal diagnosis by massively parallel sequencing of maternal plasma DNA. Open Biol. 2012 Jun; 2(6):120086. 28. Fisher J. First-trimester screening: dealing with the fall-out. Prenat Diagn. 2011; Jan;31(1):46-9 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59012 | - |
| dc.description.abstract | 唐氏症是新生兒最常見的染色體異常,隨著篩檢工具及篩檢策略的演進,篩檢的偽陽性得以降低而偵測率則可以得到提昇。當孕婦有越來越多種不同的選擇,在遺傳諮詢時卻發現孕婦會因篩檢結果而遭遇到更多心理衝擊與疑惑。
本研究目的在瞭解孕婦接受唐氏症篩檢的種類及選擇的原因,並了解孕婦對篩檢的了解與接受度。採橫斷式調查性研究,對象為懷孕20~26週完成唐氏症篩檢或胎兒染色體檢查之孕婦,經個案同意後以問卷及相關產檢報告收集資料。問卷內容包括「個案基本資料」、「唐氏症篩檢種類」、「選擇篩檢的原因」、「接受胎兒染色體檢查的原因」、「對疾病及檢查的認知情形」及「對篩檢的接受度與諮詢需求」。 研究結果發現孕婦的年齡、教育程度、有無職業、及胎次等對唐氏症的認識並無差異。疾病本身相關知識、遺傳模式並不是孕婦最關注的部分,疾病篩檢流程在病患而言也是陌生複雜的概念,孕婦不認為或沒有充分的自信為自己做決定。因此決定篩檢的因素中最重要的仍是醫師建議,其次才是與篩檢本身有關的特性(準確率、費用),除了專業人員,親友及網路資料也是影響孕婦選擇的重要因素。 唐氏症篩檢對大多數的孕婦而言可以符合其期待,而孕婦對疾病的焦慮也可藉篩檢而減輕,但他們在孕期中的諸多疑問仍需要諮詢協助。儘早開始、個別化的諮詢可以讓孕婦在進行篩檢前有更多時間思考,了解自己的價值取捨,做下符合個人需求的決定。 | zh_TW |
| dc.description.abstract | Objective
Down screen has been widely used in clinical practice for decades. Pregnant women take the test as part of routine antenatal care; however, they only have limited knowledge about Down syndrome and the test they chose. The aims of this study are to (1) investigate factors influencing the choose of Down screen (2) identify the degree of perception about Down syndrome and screening test, and (3) comprehend the impression and demands of pregnant women after completing screening test. Methods A cross-sectional survey was undertaken to collect data from one community hospital and two clinic units. Women at 20 + 0 to 26+0 weeks' gestation receiving prenatal Down screen or chromosomal study were enrolled in this study. The survey queries include four parts: the demographic characteristics, perception about disease and test, type of tests and reasons of choosing tests, and demands after test. Participants used scales to indicate level of agreement with statement of questions. Demographic data were calculated with descriptive statistics and the correlation study was calculated with Spearman rank correlation analysis. Result In total five hundred pregnant women participated in this study. Women with conditions of multiple pregnancy, abnormal screening result, and known fetal anomaly in current or previous pregnancy were excluded. Three hundred and five women completing the queries were enrolled. Fifty out of seventy-six pregnant women of advanced age (34 years old and over) received chromosomal study without any screening test; two hundred and forty seven women received Down screen tests. Maternal age, parity, occupation, and education level are not correlated with the understanding of Down syndrome or screening test. 73.7% of the women had confident cognition about Down syndrome, and only 56.4% parents understood the etiology and inherit pattern of disease. More women concerned the accuracy of test (81.4%) and most of the participant (82.3%) understood that screen test is not a diagnosis. The quadruple test is most frequently used (46.2%), the next frequent is first trimester combine test (35.2%) and integrate test is less accepted (0.8%). The factors affecting decision making include suggestion from physician (67.2%), accuracy of test (32.8%), more disease can be detected at the time (12.6%), information from internet (12.6%), and introduced by relatives and friends(8.9%). 97.6% of the women reported that their expectation of screening test has been fulfilled. 86.6% of the women can comprehend the result, but 42.1% need more discussion about the detail of report. Though the degree of anxiety was alleviated in 89.5% after receiving test, 45.7% of pregnant women, especially nulliparous, still need counseling. Conclusion Down screen is not offered to all pregnant women. Only 27.6% women of advanced age receiving Down screen; most of them are perceived as being at high risk and encouraged to take chromosomal test directly. Information of disease and theories of tests are not the concern of women. Individual counseling should be provided to all pregnant women. Adequate information and time for consideration should be given by health professionals before conducting test. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T08:44:27Z (GMT). No. of bitstreams: 1 ntu-102-P97448012-1.pdf: 2180105 bytes, checksum: 21fd42a77956553ea6e1075cbfebab28 (MD5) Previous issue date: 2013 | en |
| dc.description.tableofcontents | 口試委員會審定書……………………………………………1
誌謝………………………………………………………………2 中文摘要…………………………………………………………7 英文摘要…………………………………………………………8 第一章 緒論 第一節 研究背景與動機………………………………11 第二節 研究目的………………………………………12 第二章 文獻探討 第一節 唐氏症的疾病介紹…………………………14 第二節 唐氏症診斷方式……………………………………15 第三節 以孕婦年齡作為篩檢條件…………………………16 第四節 母血血清生化篩檢…………………………………17 第五節 非侵入性胎兒染色體檢測…………………………18 第六節 早孕期超音波檢查及血清生化綜合篩檢…………19 第七節 第一孕期唐氏症篩檢結合第二孕母血唐氏症篩檢..23 第三章 研究方法 第一節 研究對象…………………………………………25 第二節 研究工具…………………………………………25 第三節 資料收集………………………………………25 第四節 統計分析……………………………………26 第四章 結果統計………………………………………27 第五章 結果討論 第一節 受訪孕婦背景與疾病了解………………30 第二節 相關性分析………………………………30 第三節 研究檢討與侷限…………………………………32 第六章 結論…………………………………………………33 圖表……………………………………………………………………37 參考文獻……………………………………………………………48 附錄 1.訪談大綱……………………………………………………52 2.問卷……………………………………………………………54 | |
| dc.language.iso | zh-TW | |
| dc.subject | 唐氏症篩檢 | zh_TW |
| dc.subject | 高齡 | zh_TW |
| dc.subject | 病患自主 | zh_TW |
| dc.subject | 選擇因素 | zh_TW |
| dc.subject | 遺傳諮詢 | zh_TW |
| dc.subject | advanced maternal age | en |
| dc.subject | factors affecting the choice | en |
| dc.subject | genetic counseling | en |
| dc.subject | Down screen | en |
| dc.subject | patient autonomy | en |
| dc.title | 影響懷孕婦女對不同唐氏症篩檢選擇的因素與後續遺傳諮詢需求 | zh_TW |
| dc.title | Factors affecting the choice of Down screen and acceptance of counseling in pregnant women | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 101-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 陳明,李妮鍾 | |
| dc.subject.keyword | 唐氏症篩檢,高齡,病患自主,選擇因素,遺傳諮詢, | zh_TW |
| dc.subject.keyword | Down screen,advanced maternal age,patient autonomy,factors affecting the choice,genetic counseling, | en |
| dc.relation.page | 56 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2013-08-22 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
| 顯示於系所單位: | 分子醫學研究所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-102-1.pdf 未授權公開取用 | 2.13 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
